



Eurofins Discovery Services Luxembourg Holding exceeds 50% stake in Cerep S.A. (excluding shares being purchased in the public tender offer)

12 February 2013

Eurofins Discovery Services Luxembourg Holding (EDSL), a wholly-owned subsidiary of Eurofins Scientific (EUFI.PA), announces that it has acquired over 50% of the share capital of Cerep S.A., apart from the shares that are currently being purchased through the public tender offer which commenced on the 24th of January, 2013.

The result of the public tender offer, which expires on the 27th of February, 2013, will determine how much of the share capital of Cerep S.A. EDSL has acquired. Furthermore, the Autorité des Marchés Financiers (AMF) may decide to extend the tender offer period for another 10 trading days commencing on the 11th of March, 2013 to allow additional Cerep shareholders to avail of the offer. Therefore, final ownership level will likely be determined after the result of the extended tender offer, expected to be announced by the AMF by the 28th of March, 2013.

The shares already acquired by EDSL representing over 50% of the total share capital of Cerep S.A. had been acquired through private placements and from the open market, separate from the public tender offer. As previously communicated, EDSL launched the tender offer, which was supported by the Board of Directors of Cerep S.A, at a price of EUR 2 per share¹.

¹ Eurofins announcement dated 23 January 2013 (<http://www.eurofins.fr/fr-fr/informations-media/communiqués-de-presse/2013-01-23.aspx>).

For more information, please visit www.eurofins.com or contact:

Eurofins Investor Relations
Phone: +32-2-766 1620
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics, discovery pharmacology and central laboratory services.

With over 13,000 staff in more than 170 laboratories across 34 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological

substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.